KD Pharma adds to omega-3 API production supply chain with UK site

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/dutko)
(Image: Getty/dutko)

Related tags: API, Supply chain, Manufacturing, Production line, Omega-3 fatty acid, Pharmaceutical companies

KD Pharma adds manufacturing site in Seal Sands, UK, to manufacture omega-3-based intermediates for use in API production.

With seven sites across Europe and the US, KD Pharma aims to add on to the growing omega-3 active pharmaceutical ingredient (API) market. The company produces omega-3 products for the use in finished products, such as soft gel capsules and bottled liquid forms of pharmaceutical products.

With the acquisition of the UK manufacturing site, KD Pharma will be able to meet the market demand for supplying the omega-3 APIs for product approvals, label expansions, and clinical research of drug candidates.

Oscar Groet, CEO of KD Pharma, said in a statement that this site acquisition will expand the company’s technology and manufacturing base for producing API’s that have the highest concentrations of EPA and DHA omega-3s.

The Seal Sands site, which was previously used for the manufacturing of omega-3 products, will be brought online for intermediate production later this year.

Related news

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more